+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Shingles Vaccine Market - Global Forecast 2025-2032

  • PDF Icon

    Report

  • 187 Pages
  • October 2025
  • Region: Global
  • 360iResearch™
  • ID: 5716361
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The shingles vaccine market continues to evolve, driven by advances in immunization technology, updated public health strategies, and a growing demand among aging populations. This report provides senior decision-makers with foundational insights and actionable intelligence to support critical planning in a shifting healthcare landscape.

Market Snapshot: Shingles Vaccine Market Growth Trajectory

The shingles vaccine market grew from USD 1.87 billion in 2024 to USD 2.02 billion in 2025. Sustained by a CAGR of 8.36%, the market is projected to reach USD 3.56 billion by 2032. This growth is influenced by rising herpes zoster incidence among older adults, increased awareness of postherpetic neuralgia, and healthcare system initiatives to reduce age-related disease burdens.

Scope & Segmentation of the Shingles Vaccine Market

This research provides an in-depth analysis of the shingles vaccine landscape, emphasizing opportunities and strategies across regions, vaccine types, and pathways to market. The study encompasses the following segmentation fields:

  • Vaccine Types: Recombinant Zoster Vaccine, Zoster Vaccine Live
  • Age Groups: 50 to 59 Years, 60 to 69 Years, 70 Years and Above
  • End Users: Community Clinics, Private Clinics, General Hospitals, Specialty Hospitals
  • Distribution Channels: Hospital Pharmacies, Digital Pharmacies, E-commerce Platforms, Chain Pharmacies, Independent Pharmacies
  • Dosage Options: Multi Dose, Single Dose
  • Regions: North America (United States, Canada, Mexico), Latin America (Brazil, Argentina, Chile, Colombia, Peru), Europe (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland), Middle East (United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel), Africa (South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
  • Leading Companies: GlaxoSmithKline plc, Merck & Co., Inc., SK chemicals, GeneOne Life Science, CanSinoBIO, Moderna, Inc., Chengdu Institute of Biological Products Co., Ltd., Beijing Institute of Biological Products Co., Ltd., Yuxi Walvax Biotechnology Co., Ltd.

Key Takeaways for Strategic Decision-Making

  • Recombinant vaccines are gaining preference, reflecting innovation in immunization methods and improved safety for older populations.
  • Technological advancements, such as enhanced adjuvant systems and digital supply tracking, are reshaping vaccine development and deployment.
  • Emerging mRNA-based candidates indicate ongoing pipeline diversification in shingles prevention approaches, creating new collaboration pathways for biotech and pharmaceutical firms.
  • Market dynamics vary by region, with developed economies prioritizing centralized immunization programs and emerging markets investing in cold chain infrastructure and public sector channels.
  • Strategic collaborations are accelerating product innovation, optimizing manufacturing capacity, and supporting efficient knowledge transfer across the industry.
  • Segmented outreach through tailored clinic and pharmacy channels supports broader immunization rates and improves logistical efficiency.

Tariff Impact on Supply Chains and Pricing

Recent tariff measures in the United States have increased procurement costs for pharmaceutical components integral to shingles vaccine manufacturing. These policies prompted greater interest in nearshoring and boosted investments in domestic production to reduce exposure to trade-driven risks. Manufacturers now favor local bioprocessing and collaboration with contract development organizations, ensuring a more resilient and diversified supply chain despite cost challenges.

Methodology & Data Sources

The analysis integrates a detailed literature review of peer-reviewed journals, government reports, and policy documents with targeted interviews of clinicians, regulators, and supply chain experts. Frameworks such as SWOT and PESTEL analyses provide structure to evaluate drivers and constraints. All proprietary inputs were anonymized and aggregated to preserve confidentiality and ensure reliable findings.

Why This Report Matters

  • Supports evidence-based strategic planning for market entry, supply chain realignment, and R&D investments in the shingles immunization domain.
  • Enables optimized allocation of resources by pinpointing high-growth segments, regional priorities, and shifting stakeholder needs.
  • Equips leaders with actionable insights into competitive developments, regulatory changes, and technology adoption critical for long-term success.

Conclusion: Future Outlook for the Shingles Vaccine Market

The shingles vaccine market is set for continued transformation as innovation, collaboration, and adaptive strategies redefine the immunization landscape. Organizations embracing technology, segmentation, and stakeholder engagement will be positioned for growth and market leadership.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Rapid global uptake of recombinant adjuvanted shingles vaccines in adults over 50
5.2. Integration of shingles immunization into routine adult vaccination schedules by national agencies
5.3. Growing investment in next generation herpes zoster vaccine candidates leveraging novel mRNA technology
5.4. Heightened focus on vaccine access programs in emerging markets to close shingles immunization gaps in seniors
5.5. Rising consumer awareness campaigns highlighting long term efficacy and safety profiles of newer shingles vaccines
5.6. Collaborative research partnerships between biotech start ups and big pharma to develop next generation zoster immunogens
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Shingles Vaccine Market, by Vaccine Type
8.1. Recombinant Zoster Vaccine
8.2. Zoster Vaccine Live
9. Shingles Vaccine Market, by Age Group
9.1. 50 To 59 Years
9.2. 60 To 69 Years
9.3. 70 Years and Above
10. Shingles Vaccine Market, by End User
10.1. Clinics
10.1.1. Community Clinics
10.1.2. Private Clinics
10.2. Hospitals
10.2.1. General Hospitals
10.2.2. Specialty Hospitals
11. Shingles Vaccine Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.2.1. Digital Pharmacies
11.2.2. E-commerce Platforms
11.3. Retail Pharmacies
11.3.1. Chain Pharmacies
11.3.2. Independent Pharmacies
12. Shingles Vaccine Market, by Dosage
12.1. Multi Dose
12.2. Single Dose
13. Shingles Vaccine Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Shingles Vaccine Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Shingles Vaccine Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. GlaxoSmithKline plc
16.3.2. Merck & Co., Inc.
16.3.3. SK chemicals
16.3.4. GeneOne Life Science
16.3.5. CanSinoBIO
16.3.6. Moderna, Inc.
16.3.7. Chengdu Institute of Biological Products Co., Ltd.
16.3.8. Beijing Institute of Biological Products Co., Ltd.
16.3.9. Yuxi Walvax Biotechnology Co., Ltd.
List of Tables
List of Figures

Samples

Loading
LOADING...

Companies Mentioned

The key companies profiled in this Shingles Vaccine market report include:
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • SK chemicals
  • GeneOne Life Science
  • CanSinoBIO
  • Moderna, Inc.
  • Chengdu Institute of Biological Products Co., Ltd.
  • Beijing Institute of Biological Products Co., Ltd.
  • Yuxi Walvax Biotechnology Co., Ltd.

Table Information